Greer Labs and Stallergenes in deal for Oralair in USA

French allergy specialists Stallergenes (Euronext Paris: GENP) and USA-based Greer Laboratories have signed an exclusive agreement for the US commercialization rights to Oralair, an investigational grass allergy immunotherapy tablet currently under review by the Food and Drug Administration.

Under the terms of the accord, Greer, which earlier this year was acquired by Switzerland-based Ares Life Sciences, the health care investment firm established by the Bertarelli family (The Pharma Letter March 8), will lead the sales and marketing efforts for Oralair in the USA and Stallergenes will be responsible for tablet production and supply.

$120 million regulatory and commercial milestones for French firm

Stallergenes will receive regulatory and commercial milestone payments totalling up to $120 million plus royalties and a transfer price. Oralair is already marketed in several European countries, as well as Australia and Canada.